Want to see KR:092730 full AI Analyst Report?

NeoPharm Co., Ltd. (092730) Price & Analysis

― Followers

092730 Stock Chart & Stats

₩22300.00

₩550.00(2.53%)

Oct 29, 2026

―

Day’s Range― - ―

52-Week Range₩15,590.00 - ₩26,000.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)41.27K

Market Cap

₩348.80B

Enterprise Value₩141.49B

Total Cash (Recent Filing)₩147.59B

Total Debt (Recent Filing)₩1.65B

Price to Earnings (P/E)6.1

Beta0.09

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.33%

Share Statistics

EPS (TTM)1873.90

Shares Outstanding16,027,988

10 Day Avg. Volume39,277

30 Day Avg. Volume41,266

Financial Highlights & Ratios

PEG Ratio0.32

Price to Book (P/B)0.93

Price to Sales (P/S)1.38

P/FCF Ratio6.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)2,013

Revenue Forecast (FY)₩168.00B

Bulls Say, Bears Say

Bulls Say

Revenue And Earnings GrowthAccelerating revenue accompanied by higher earnings indicates that NeoPharm is converting stronger demand into bottom-line growth. If this performance continues, the company should have greater capacity to reinvest in product development, expand commercialization, and strengthen its competitive position over the next several quarters.

Strong ProfitabilityPersistently high gross and net profitability provides NeoPharm with meaningful economic resilience and internal funding capacity. Strong margins can support continued investment in pharmaceuticals and health products while helping the company absorb moderate cost pressure without immediately undermining earnings quality.

Conservative Balance SheetVery low leverage materially reduces financial strain and gives NeoPharm flexibility to fund expansion without relying heavily on borrowing. Growing equity and assets further support balance-sheet durability, allowing the company to withstand weaker periods and preserve options for long-term capital allocation.

Bears Say

Margin CompressionThe decline in operating and cash earnings margins suggests that recent growth has not fully translated into expanding profitability. If margin pressure persists as revenue growth normalizes, earnings could grow more slowly and the company may have less internal cash available for development and commercialization.

Volatile Free Cash FlowAlthough operating cash generation is generally strong, substantial year-to-year free-cash-flow swings make cash conversion less predictable. This variability can complicate investment planning and reduce confidence that reported earnings will consistently translate into discretionary funds for expansion, dividends, or other uses.

Variable Shareholder ReturnsHealthy returns on equity are a strength, but their year-to-year fluctuation indicates that capital efficiency is not completely consistent. Continued variability could make future earnings productivity less predictable and may limit the reliability of return-based performance as growth and margins evolve.

092730 FAQ

What was NeoPharm Co., Ltd.’s price range in the past 12 months?

NeoPharm Co., Ltd. lowest stock price was ₩15590.00 and its highest was ₩26000.00 in the past 12 months.

What is NeoPharm Co., Ltd.’s market cap?

NeoPharm Co., Ltd.’s market cap is ₩348.80B.

When is NeoPharm Co., Ltd.’s upcoming earnings report date?

NeoPharm Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 6 days.

How were NeoPharm Co., Ltd.’s earnings last quarter?

NeoPharm Co., Ltd. released its earnings results on Aug 14, 2026. The company reported ₩537.374 earnings per share for the quarter.

Is NeoPharm Co., Ltd. overvalued?

According to Wall Street analysts NeoPharm Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NeoPharm Co., Ltd. pay dividends?

NeoPharm Co., Ltd. pays a Annually dividend of ₩750 which represents an annual dividend yield of 5.33%. See more information on NeoPharm Co., Ltd. dividends here

What is NeoPharm Co., Ltd.’s EPS estimate?

NeoPharm Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NeoPharm Co., Ltd. have?

NeoPharm Co., Ltd. has 16,027,988 shares outstanding.

What happened to NeoPharm Co., Ltd.’s price movement after its last earnings report?

NeoPharm Co., Ltd. reported an EPS of ₩537.374 in its last earnings report. Following the earnings report the stock price went down -0.615%.

Which hedge fund is a major shareholder of NeoPharm Co., Ltd.?

Currently, no hedge funds are holding shares in KR:092730

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NeoPharm Co., Ltd.

NeoPharm Co., Ltd. focuses on the invention, manufacturing, and distribution of various cosmetic, medical, and health-related goods. Their product line features advanced emulsified and specialized skincare solutions, particularly designed for individuals with sensitive or dry skin. Additionally, the company provides treatments for ailments like atopic dermatitis and psoriasis, alongside therapies aimed at mitigating the side effects of steroid use. Established on July 1, 2000, the firm's main office is situated in Daejeon, South Korea.